CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Xavier Pivot,Alexey Manikhas,Bogdan Żurawski,Ewa Chmielowska,Boguslawa Karaszewska,Rozenn Allerton,Stephen Chan,Alessandra Fabi,Paolo Bidoli,Stefania Gori,Eva Ciruelos,Magdolna Dank,Lajos Hornyak,Sara Margolin,Arnd Nusch,R. Parikh,Fareha Nagi,Michelle DeSilvio,Sergio Santillana,Ramona F. Swaby,Vladimir Semiglazov

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

2015

Purpose CEREBEL compared the incidence of CNS metastases as first site of relapse in patients with human epidermal growth factor receptor 2‐positive metastatic breast cancer receiving lapatinibcapecitabine or trastuzumab-capecitabine.

Keywords:

Capecitabine
Human epidermal growth factor
Trastuzumab
Lapatinib
Medicine
Human Epidermal Growth Factor Receptor 2
Internal medicine
Receptor
Metastatic breast cancer
Oncology
Loading dose
Monoclonal
in patient
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

161

Citations